Vancouver, British Columbia–(Newsfile Corp. – September 21, 2021) – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company“), a Company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, announced today it has entered into an agreement with Johns Hopkins University School of Medicine (JHU) to develop image reconstruction software (deep machine learning algorithms) to further improve the image processing performance of Breast CT while minimizing computational burden1.
JHU is recognized as a world leader in the development of image processing machine learning algorithms. The development will be led by Dr. Alejandro Sisniega-Crespo2, a Research Associate in JHU’s Department of Biomedical Engineering and an expert in tomographic reconstruction methods, in collaboration with IzoView Founder and Company Director Dr. John Boone and others from the University of California Davis. Izotropic expects the collaboration will result in a novel set of learning-based approaches for accurate identification and characterization of breast pathologies.
Izotropic is working to bring breakthrough developments in methods integrating data-based machine learning approaches to reduce noise and image biases with the preservation of the intrinsic spatial resolution of the IzoView system. Combining the true 3D high-resolution nature of IzoView breast CT with the expected excellent soft-tissue contrast provided by the reconstruction methods, IzoView will offer an outstanding platform for the development and implementation of a novel set of learning-based approaches for accurate identification and characterization of breast pathologies.
Software development is underway and will integrate into the fabrication of the Company’s initial IzoView clinical study units. Clinical study units will include an enhanced product design and performance improvements for added usability to increase competitive advantages, a broadened product offering, and attract a larger target market.
IzoView produces high-resolution breast images in true 3D and is ideal for imaging patients with dense breast tissue. A single 10-second scan acquires approximately 500 images without painful breast compression or continual technician breast handling, providing a more comfortable patient experience with low radiation dose levels.
In addition to improved detection capabilities, Izotropic anticipates IzoView’s higher resolution 3D images could provide more accurate margin analysis (viewing edges of a tumor), lesion characterization (determining the qualities of an abnormality), and higher spatial resolution (the imaging ability to differentiate between internal breast structures).
ON BEHALF OF THE COMPANY
Dr. John McGraw, CEO
For investor relations inquiries, contact:
Email: [email protected]
Toll Free: 1-833-IZOCORP ext.1
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic’s initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. In follow-on clinical studies, Izotropic intends to validate platform applications including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the Company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.
1 The amount of resources required to run the algorithm.
2 Dr. Sisniega-Crespo’s bio can be found at https://www.bme.jhu.edu/people/faculty/alejandro-sisniega-crespo/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97116